tadalafil has been researched along with Urinary Bladder, Overactive in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 12 (63.16) | 24.3611 |
| 2020's | 7 (36.84) | 2.80 |
| Authors | Studies |
|---|---|
| Fujihara, A; Harikai, S; Hirahara, N; Ukimura, O; Ushijima, S; Yamada, Y | 1 |
| Fujimoto, K; Gotoh, D; Hori, S; Miyake, M; Morizawa, Y; Nakai, Y; Torimoto, K | 1 |
| Araki, K; Matsuo, T; Miyata, Y; Mukae, Y; Ohba, K; Otsubo, A; Sakai, H | 1 |
| Fuse, M; Kaga, K; Kageyama, S; Sakata, K; Tokunaga, S; Yamanishi, T; Yokoyama, T | 1 |
| Wein, AJ | 1 |
| Burnett, AL; Feng, Q; Hairston, JC; Johnston, KM; Lozano-Ortega, G; Nimke, D; Walker, DR | 1 |
| Higashi, Y; Kuwahara, Y; Nakamura, K; Shimura, H; Takeda, M; Tsukamoto, T; Watanabe, N | 1 |
| Pannek, J | 1 |
| Fonteles, MC; Gonzaga-Silva, LF; Linhares, BL; Marinho, LB; Moraes, MO; Nascimento, NRF; Reges, R; Santos, CF; Silva, APG | 1 |
| Funahashi, Y; Gotoh, M; Kato, M; Majima, T; Matsukawa, Y; Sassa, N; Takai, S; Yamamoto, T | 1 |
| Barreira, MA; Carvalho, MF; Fechine, FVJ; Gonzaga-Silva, LF; Oliveira, RRM; Pamplona, TL | 1 |
| de Groat, WC | 1 |
| Dell'Atti, L | 1 |
| Hikita, K; Honda, M; Kawamoto, B; Morizane, S; Muraoka, K; Sejima, T; Takenaka, A | 1 |
| Chen, B; Chen, H; Dai, S; Liu, C; Lv, J; Wang, F; Yu, Z; Zhang, Y | 1 |
| Feng, D; Tang, Y | 1 |
| Bai, Y; Han, P; Wang, X; Yang, Y | 1 |
| Andersson, KE; Hood, B | 1 |
| Cerqueira, JB; de Moraes, MO; Jamacaru, FV; Josino, IR; Nogueira, EA; Regadas, RP; Reges, R; Silva, LF; Sucupira, DG | 1 |
2 review(s) available for tadalafil and Urinary Bladder, Overactive
| Article | Year |
|---|---|
[Overactive bladder-which treatment when?]
Topics: Behavior Therapy; Botulinum Toxins, Type A; Diagnosis, Differential; Electric Stimulation Therapy; Female; Gabapentin; Humans; Injections, Intramuscular; Lumbosacral Plexus; Male; Muscarinic Antagonists; Patient Preference; Physical Therapy Modalities; Solifenacin Succinate; Tadalafil; Urinary Bladder; Urinary Bladder, Overactive | 2017 |
Common theme for drugs effective in overactive bladder treatment: inhibition of afferent signaling from the bladder.
Topics: Acetanilides; Afferent Pathways; Animals; Botulinum Toxins, Type A; Carbolines; Humans; Phosphodiesterase 5 Inhibitors; Tadalafil; Thiazoles; Urinary Bladder, Overactive | 2013 |
5 trial(s) available for tadalafil and Urinary Bladder, Overactive
| Article | Year |
|---|---|
Efficacy of Tadalafil Therapy and Changes in Oxidative Stress Levels in Male Patients with Lower Urinary Tract Symptoms and Overactive Bladder.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Aged; Humans; Lower Urinary Tract Symptoms; Male; Oxidative Stress; Prospective Studies; Tadalafil; Treatment Outcome; Urinary Bladder, Overactive; Urodynamics; Urological Agents | 2020 |
A randomized controlled study of the efficacy of tadalafil monotherapy versus combination of tadalafil and mirabegron for the treatment of persistent overactive bladder symptoms in men presenting with lower urinary tract symptoms (CONTACT Study).
Topics: Acetanilides; Aged; Aged, 80 and over; Drug Therapy, Combination; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Prostatic Hyperplasia; Tadalafil; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence; Urination; Urological Agents | 2020 |
Efficacy of Tadalafil once daily versus Fesoterodine in the treatment of overactive bladder in older patients.
Topics: Aged; Benzhydryl Compounds; Humans; Male; Phosphodiesterase 5 Inhibitors; Quality of Life; Tadalafil; Urinary Bladder, Overactive; Urological Agents | 2015 |
Efficacy of Daily Low-dose Tadalafil for Treating Overactive Bladder: Results of a Randomized, Double-blind, Placebo-controlled Trial.
Topics: Adult; China; Double-Blind Method; Drug Administration Schedule; Female; Humans; Middle Aged; Tadalafil; Treatment Outcome; Urinary Bladder, Overactive; Urination; Urological Agents | 2017 |
Urodynamic effects of the combination of tamsulosin and daily tadalafil in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia: a randomized, placebo-controlled clinical trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Carbolines; Double-Blind Method; Drug Therapy, Combination; Humans; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Prostatism; Sulfonamides; Tadalafil; Tamsulosin; Urinary Bladder, Overactive; Urination; Urodynamics | 2013 |
12 other study(ies) available for tadalafil and Urinary Bladder, Overactive
| Article | Year |
|---|---|
Efficacy of tadalafil on symptom-specific bother in men with lower urinary tract symptoms.
Topics: Humans; Lower Urinary Tract Symptoms; Male; Phosphodiesterase 5 Inhibitors; Prospective Studies; Prostatic Hyperplasia; Quality of Life; Tadalafil; Treatment Outcome; Urinary Bladder, Overactive | 2022 |
Efficacy and safety of dutasteride with tadalafil add-on therapy in patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia.
Topics: Aged; Dutasteride; Humans; Lower Urinary Tract Symptoms; Male; Prostatic Hyperplasia; Quality of Life; Tadalafil; Urinary Bladder, Overactive | 2022 |
Re: Efficacy of Tadalafil Therapy and Changes in Oxidative Stress Levels in Male Patients with Lower Urinary Tract Symptoms and Overactive Bladder.
Topics: Humans; Lower Urinary Tract Symptoms; Male; Oxidative Stress; Tadalafil; Urinary Bladder, Overactive; Urological Agents | 2020 |
Undertreatment of overactive bladder among men with lower urinary tract symptoms in the United States: A retrospective observational study.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Drug Therapy, Combination; Humans; Male; Medicare; Middle Aged; Prostatic Hyperplasia; Retrospective Studies; Tadalafil; United States; Urinary Bladder, Overactive; Urination; Urological Agents | 2020 |
[EVALUATING THE RELATIONSHIP BETWEEN LOWER URINARY TRACT SYMPTOMS AND ENDOTHELIAL FUNCTION USING FLOW-MEDIATED DILATION, AND THE EFFECTS OF TADALAFIL].
Topics: Aged; Blood Flow Velocity; Endothelium, Vascular; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Tadalafil; Treatment Outcome; Urinary Bladder, Overactive; Vasodilation | 2020 |
Effect of co-administration of two different phosphodiesterase inhibitors and a β
Topics: Adrenergic beta-3 Receptor Agonists; Animals; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Synergism; Drug Therapy, Combination; Ethanolamines; Humans; Male; Mice; Muscle Contraction; Muscle Relaxation; Muscle, Smooth; NG-Nitroarginine Methyl Ester; Phosphodiesterase 4 Inhibitors; Phosphodiesterase 5 Inhibitors; Rolipram; Tadalafil; Treatment Outcome; Urinary Bladder; Urinary Bladder, Overactive | 2018 |
Objective impacts of tadalafil on storage and voiding function in male patients with benign prostatic hyperplasia: 1-year outcomes from a prospective urodynamic study.
Topics: Aged; Aged, 80 and over; Animals; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Prospective Studies; Prostatic Hyperplasia; Tadalafil; Urinary Bladder Neck Obstruction; Urinary Bladder, Overactive; Urodynamics; Urological Agents | 2019 |
Effect of co-administration of BRL-37344 and tadalafil on reduction of overactive bladder symptoms after induction of detrusor overactivity in mice1.
Topics: Animals; Disease Models, Animal; Drug Therapy, Combination; Ethanolamines; Male; Mice; NG-Nitroarginine Methyl Ester; Random Allocation; Tadalafil; Urinary Bladder, Overactive; Urination; Urological Agents | 2019 |
Lower urinary tract dysfunction: From basic science to clinical management. Foreword.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Afferent Pathways; Biomarkers; Botulinum Toxins; Carbolines; Humans; Lower Urinary Tract Symptoms; Phosphodiesterase 5 Inhibitors; Signal Transduction; Tadalafil; Thiazoles; Urinary Bladder, Overactive; Urothelium | 2013 |
Impact of postoperative phosphodiesterase type 5 inhibitor treatment on lower urinary tract symptoms after robot-assisted radical prostatectomy: a longitudinal study.
Topics: Aged; Humans; Longitudinal Studies; Lower Urinary Tract Symptoms; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Postoperative Care; Prostatectomy; Prostatic Neoplasms; Retrospective Studies; Robotic Surgical Procedures; Tadalafil; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence | 2017 |
Re: Chen et al.: Efficacy of Daily Low-dose Tadalafil for Treating Overactive Bladder: Results of a Randomized, Double-blind, Placebo-controlled Trial (Urology 2017;100:59-64).
Topics: Benzhydryl Compounds; Double-Blind Method; Humans; Muscarinic Antagonists; Tadalafil; Treatment Outcome; Urinary Bladder, Overactive | 2017 |
Re: Chen H. et al: Efficacy of Daily Low-dose Tadalafil for Treating Overactive Bladder: Results of a Randomized, Double-blind, Placebo-controlled Trial (Urology 2016;100:59-64).
Topics: Double-Blind Method; Humans; Muscarinic Antagonists; Tadalafil; Treatment Outcome; Urinary Bladder, Overactive | 2017 |